Overview

Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma

Status:
Terminated
Trial end date:
2003-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Current therapies for adult recurrent/progressive low grade astrocytoma provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of adult recurrent/progressive low grade astrocytoma. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on adults with a recurrent/progressive low grade astrocytoma.
Phase:
Phase 2
Details
Lead Sponsor:
Burzynski Research Institute